Overview
KLOW Blend unites GHK-Cu (50mg), TB-500 (10mg), BPC-157 (10mg), and KPV (10mg) in one pre-formulated preparation. The first three cover collagen signaling, VEGF-dependent angiogenesis, and VEGF-independent cell migration; KPV adds a fourth mechanism that works from inside the cell — giving the blend two separate entry points into inflammatory pathway modulation.
Mechanism of Action
GHK-Cu drives collagen synthesis and matrix remodeling gene programs; BPC-157 signals through VEGFR2 and FAK phosphorylation; TB-500 acts via integrin αvβ3, Akt-eNOS, and actin-mediated migration. KPV completes the profile: transported into cells through PepT1, it directly inhibits IκB kinase and blocks NF-κB nuclear translocation in immune and epithelial preparations — suppressing pro-inflammatory cytokine expression intracellularly, a route mechanistically distinct from TB-500's extracellular inflammatory modulation. The blend therefore addresses NF-κB pathway activity at two separate points in the cascade.
Specifications
- Purity: ≥99% (HPLC) with mass-spectrometry identity confirmation
- Form: Lyophilized powder, pre-blended
- Composition: GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg
- CAS Numbers: GHK-Cu: 49557-75-7 · BPC-157: 137525-51-0 · TB-500: 77591-33-4 · KPV: 66172-75-6
- Molecular Weights: GHK-Cu: 403.92 Da · BPC-157: 1419.53 Da · TB-500: 4963.44 Da · KPV: 358.44 Da
Research Applications
- Multi-mechanism tissue repair modeling
- Dual NF-κB pathway inhibition studies
- Collagen synthesis and ECM remodeling
- PepT1-mediated intracellular signaling
- Dual-mechanism angiogenesis research
- Mucosal and epithelial inflammation models





